Results 101 to 110 of about 33,349 (194)

Increased cervical cancer incidence in the target age of screening—Variation by mode of detection

International Journal of Cancer, Volume 159, Issue 2, Page 359-367, 15 July 2026.
What's new? Cervical cancer rates have risen in several high‐income countries despite advances in screening. Here, using data on cervical cancer diagnoses between 1996 and 2022 in Finland, the authors examined incidence trends according to detection mode—screening, between screenings, or outside screening programs—with attention to the role of human ...
Jenna Snellman, Maiju Pankakoski, Sirpa Heinävaara, Veli‐Matti Partanen, Maija Vahteristo   +4 more
wiley   +1 more source

Integrative literature review on human papillomavirus vaccination recommendations in national immunization programs in select areas in the Asia-Pacific region

Human Vaccines & Immunotherapeutics
There is limited literature on current human papillomavirus (HPV) vaccination in the Asia-Pacific region. This integrative literature review was conducted to describe HPV vaccination programs in Hong Kong, Indonesia, Japan, South Korea, Malaysia, the ...
Wanatpreeya Phongsamart, Pei-Jen Lou, Isaya Sukarom, Ying-Hui Wu, Omer Zaidi, Frieda Du, Alyssa Simon, Mark Bernauer   +7 more
doaj   +1 more source

Cervical Cancer Awareness and Attitude Towards Cervical Cancer Screening and Human Papillomavirus Vaccines Among Urban Women of Karachi, Pakistan. [PDF]

Cureus, 2023
Shahnaz S, Fricovsky E, Anwar R, Arain MI.   +3 more
europepmc   +1 more source

Cost‐effectiveness of risk‐stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage

International Journal of Cancer, Volume 159, Issue 2, Page 389-400, 15 July 2026.
What's new? Effective cervical cancer prevention centers around screening and testing for human papillomavirus (HPV) infection. With birth cohorts of HPV‐vaccinated women now reaching screening‐eligible ages, however, the best means to maintaining cost‐effective cervical cancer screening is unclear.
Tiago M. de Carvalho, Johannes Berkhof, Johannes A. Bogaards   +2 more
wiley   +1 more source

Efficacy of prophylactic human papillomavirus vaccines on cervical cancer among the Asian population: A meta-analysis. [PDF]

Front Microbiol, 2022
Ren X, Hao Y, Wu B, Jia X, Niu M, Wang K, Li Z.   +6 more
europepmc   +1 more source

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants. [PDF]

Hum Vaccin Immunother, 2022
Garland SM, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, Group T, Lin J, Luxembourg A, Walia A, Tu Y.   +10 more
europepmc   +1 more source

Intralesional bivalent and quadrivalent human papillomavirus vaccines didn't significantly enhance the response of multiple anogenital warts when co-administered with intralesional Candida antigen immunotherapy. A randomized controlled trial. [PDF]

Arch Dermatol Res, 2023
Fawzy M, Nofal E, Abdelkhalek N, Ehab R.
europepmc   +1 more source

Ethical Challenges to Improving Access to Human Papillomavirus Vaccines in Low- and Middle-Income Countries. [PDF]

NEJM Evid, 2022
Eke AC, Kerry VB.
europepmc   +1 more source

On Imported and Domestic Human Papillomavirus Vaccines: Cognition, Attitude, and Willingness to Pay in Chinese Medical Students. [PDF]

Front Public Health, 2022
Zhou L, Gu B, Xu X, Li Y, Cheng P, Huo Y, Liu G, Zhang X.   +7 more
europepmc   +1 more source

Trends in the Utilization of Human Papillomavirus Vaccines and the Incidence of Malignant Cervical Cancer in Women and Teenagers: A Secondary Analysis. [PDF]

Healthcare (Basel), 2022
Luna M, Upadhyay S.
europepmc   +1 more source